Skip to main content

Table 3 Overview of pooled results of the prognostic value of hematologic parameters

From: Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis

 

Outcome

No.

HR

95% CI

P

I-squared (%)

P H

NLR

OS

26

1.55

1.37–1.76

0.000

83.0

0.000

CSS

4

1.14

0.89–1.45

0.297

61.5

0.050

PFS

12

1.62

1.29–2.04

0.000

67.6

0.000

DMFS

2

1.81

0.55–6.01

0.330

92.3

0.000

RFS

6

1.12

1.04–1.20

0.002

0.0

0.560

PLR

OS

6

1.72

1.36–2.18

0.000

0.0

0.575

CSS

3

1.56

0.82–2.97

1.000

78.7

0.009

PLT

OS

3

1.00

0.98–1.02

0.910

59.3

0.086

CSS

4

1.00

0.99–1.01

0.850

15.4

0.315

LMR

OS

2

2.27

1.76–2.94

0.000

27.8

0.239

PFS

2

2.18

1.58–3.02

0.000

0.0

0.460

Lymphocyte

OS

4

0.96

0.83–1.10

0.710

0.0

0.529

CSS

3

0.85

0.66–1.09

0.190

0.0

0.523

RFS

2

1.06

0.96–1.16

0.260

0.0

0.824

Neutrophil

OS

3

1.10

1.03–1.18

0.006

0.0

0.604

CSS

2

1.12

0.99–1.25

0.065

0.0

0.771

RFS

2

1.03

0.98–1.09

0.188

0.0

0.421

Monocyte

OS

3

2.25

1.67–3.05

0.000

1.54

0.463

PFS

3

1.75

1.36–2.25

0.000

33.2

0.224

  1. OS, overall survival; CSS, cancer-specific survival; PFS, progression-free survival; DMFS, distant metastases-free survival; RFS, recurrence-free survival; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PLT, platelet; HR, hazard ratio; CI, confidence intervals; PH, heterogeneity of P-value
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us